Compare Incyte Corporation (INCY) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Petróleo Brasileiro SA — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while Petróleo Brasileiro SA trades at $18.44 (market cap $108.78B). The key difference: Petróleo Brasileiro SA is far larger — about 4.7× Incyte Corporation's market cap, and Petróleo Brasileiro SA pays a 9.81% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PBR | |
|---|---|---|
Market Cap | $23.11B | $108.78B |
Sector | Health | Technology |
52-Week High | $118.52 | $22.03 |
52-Week Low | $67.38 | $11.54 |
Enterprise Value | $19.13B | $171.32B |
Dividend Yield | — | 9.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Petrobras (PBR) trades at $18.19, up 1.22% with bullish technical indicators and strong fundamentals. The stock shows robust profitability with 21.47% net margins and attractive valuation at 5.73 P/E. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. The company maintains strong cash flow generation of $197.5B operating cash flow in 2025 and recently announced strategic acquisitions and renewable energy investments.
PBR presents compelling value with deep discount valuation and 50% analyst buy ratings. Key opportunities include production growth initiatives and dividend sustainability, while risks involve commodity price volatility and geopolitical factors in Latin American operations. The stock's current technical strength combined with fundamental undervaluation supports a positive medium-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
